

# International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,<sup>1</sup> notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 63 Prop. INN not later than 31 January 1991.

*The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.*

## Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INNs. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will be neither revised nor included in the Cumulative Lists of INN.

## Proposed International Nonproprietary Names (Prop. INN): List 63<sup>2</sup>

Comprehensive information on the INN programme can be found in WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances* twentieth report of the WHO Expert Committee), ISBN 92 4 120581 4 (price Sw. fr. 6.—), an account of this publication will be found in Annex 2 of the present List. All names from Lists 1–58 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances Cumulative List No. 7, 1988*, World Health Organization, Geneva (ISBN 92 4 0560149) (price: Sw. fr. 65.—). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to March 1988. The printout also indicates in which of the 58 individual lists of proposed names and 27 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

<sup>1</sup> Text adopted by the Executive Board of WHO in resolution EB15 R7 (*Off. Rec. Wld Hlth Org.*, 1955, **60**, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1969, **173**, 10).


<sup>2</sup> Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 7, 1988*.

*Proposed International  
Nonproprietary Name (Latin, English)*

*Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use*


acidum penteticum  
pentetic acid

*N,N*-bis[2-[bis(carboxymethyl)amino]ethyl]glycine  
C<sub>14</sub>H<sub>23</sub>N<sub>3</sub>O<sub>10</sub> 67-43-6 *diagnostic aid*




adaprololum  
adaprolol

2-(1-adamantyl)ethyl (±)-[*p*-[2-hydroxy-3-(isopropylamino)-propoxy]phenyl]acetate  
C<sub>26</sub>H<sub>39</sub>NO<sub>4</sub> 101479-70-3 *β-adrenoreceptor antagonist*




adosopinum  
adosopine

*N*-(5,6-dihydro-5-methyl-6,11-dioxo-10-morphanthridinyl)acetamide  
C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> 88124-26-9 *urinary incontinence agent*



afalaninum  
afalanine

*N*-acetyl-3-phenyl-DL-alanine or *N*-acetyl-DL-phenylalanine  
C<sub>11</sub>H<sub>13</sub>NO<sub>3</sub> 2901-75-9 *antidepressant*




aldesleukinum  
aldesleukin

125-L-serine-2-133-interleukin 2 (human reduced)  
C<sub>690</sub>H<sub>1115</sub>N<sub>177</sub>O<sub>203</sub>S<sub>6</sub> 110942-02-4 *immunomodulator*

asobamastum  
asobamast

2-ethoxyethyl [4-(3-methyl-5-isoxazolyl)-2-thiazolyl]oxamate  
C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>5</sub>S 104777-03-9 *antiallergic, antiasthmatic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


berlafenonum  
berlafenone

(±)-1-(2-biphenyloxy)-3-(*tert*-butylamino)-2-propanol  
C<sub>19</sub>H<sub>25</sub>NO<sub>2</sub> 18965-97-4 *antidysrhythmic*




bidisomidum  
bidisomide

(±)- $\alpha$ -(*o*-chlorophenyl)- $\alpha$ -[2-(*N*-isopropylacetamido)ethyl]-1-piperidine-  
butyramide  
C<sub>22</sub>H<sub>34</sub>ClN<sub>3</sub>O<sub>2</sub> 116078-65-0 *antidysrhythmic*




butixocortum  
butixocort

11 $\beta$ ,17-dihydroxy-21-mercaptopregn-4-ene-3,20-dione 17-butyrate  
C<sub>25</sub>H<sub>36</sub>O<sub>5</sub>S 120815-74-9 *anti-inflammatory, glucocorticosteroid*




caldiamidum  
caldiamide

hydrogen [N,N-bis[2-[(carboxymethyl)[(methylcarbamoyl)methyl]-  
amino]ethyl]glycinato(3-)]calcitate(1-)  
C<sub>16</sub>H<sub>27</sub>CaN<sub>5</sub>O<sub>8</sub> 128326-81-8 *diagnostic aid*



cefetecolum  
cefetecol

(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-5-thia-1-aza-  
bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7<sup>2</sup>-(*Z*)-[O-[(*S*)- $\alpha$ -carboxy-3,4-  
dihydroxybenzyl]oxime]  
C<sub>20</sub>H<sub>17</sub>N<sub>5</sub>O<sub>9</sub>S<sub>2</sub> 117211-03-7 *antibiotic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


cilobradinum  
cilobradine

(±)-3-[[1-(3,4-dimethoxyphenethyl)-3-piperidyl]methyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one  
C<sub>28</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub> 109859-50-9 *bradycardic agent*




crilvastatinum  
crilvastatin

5-oxo-L-proline. (±)-*cis*-3,3,5-trimethylcyclohexyl ester  
C<sub>14</sub>H<sub>23</sub>NO<sub>3</sub> 120551-59-9 *antihyperlipidaemic*




dacopafantum  
dacopafant

(3*R*)-3-(3-pyridyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-7-carboxamide  
C<sub>12</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> 125372-33-0 *platelet-activating factor antagonist*



docetaxolum  
docetaxol

(2*R*,3*S*)-*N*-carboxy-3-phenylisoserine. *N*-*tert*-butyl ester, 13-ester with 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate  
C<sub>43</sub>H<sub>53</sub>NO<sub>14</sub> 114977-28-5 *antineoplastic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


doramectinum  
doramectin

25-cyclohexyl-5-*O*-demethyl-25-de(1-methylpropyl)avermectin A<sub>1</sub>, or  
(2*aE*,4*E*,8*E*)-(5'*S*,6*S*,6'*R*,7*S*,11*R*,13*S*,15*S*,17*aR*,20*R*,20*aR*,20*bS*)-6'-cyclohexyl-  
5',6,6',7,10,11,14,15,17*a*,20,20*a*,20*b*-dodecahydro-20,20*b*-dihydroxy-5',6,8,19-  
tetramethyl-17-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo-  
[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-7-yl 2,6-dideoxy-4-  
*O*-(2,6-dideoxy-3-*O*-methyl- $\alpha$ -L-*arabino*-hexopyranosyl)-3-*O*-methyl- $\alpha$ -L-  
*arabino*-hexopyranoside  
C<sub>50</sub>H<sub>74</sub>O<sub>14</sub> 117704-25-3 antiparasitic




drospirenonum  
drospirenone

(6*R*,7*R*,8*R*,9*S*,10*R*,13*S*,14*S*,15*S*,16*S*,17*S*)-1,3',4',6,6*a*,7,8,9,10,11,12,13,14,15,15*a*,16-  
hexadecahydro-10,13-dimethylspiro-  
[17*H*-dicyclopropa[*a*]phenanthrene-17,2'(5'*H*)-furan]-  
3,5'(2*H*)-dione  
C<sub>24</sub>H<sub>30</sub>O<sub>3</sub> 67392-87-4 progestogen




flocculidum  
flucolide

*N*-[6-(2,4-difluorophenoxy)-1-oxo-5-indanyl]methanesulfonamide  
C<sub>16</sub>H<sub>13</sub>F<sub>2</sub>NO<sub>4</sub>S 80937-31-1 nonsteroidal anti-inflammatory



fomepizolum  
fomepizole

4-methylpyrazole  
C<sub>4</sub>H<sub>6</sub>N<sub>2</sub> 7554-65-6 antidote




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


gadodiamidum  
gadodiamide

aqua[*N,N*-bis[2-[(carboxymethyl)[(methylcarbamoyl)methyl]amino]ethyl]-  
glycinato(3-)]gadolinium hydrate  
 $C_{16}H_{28}GdN_5O_9 \cdot x H_2O$  122795-43-1 *paramagnetic contrast medium*




giracodazolium  
giracodazole

( $\alpha$ S)-2-amino- $\alpha$ -[(1S)-amino-1-chloroethyl]imidazole-4-methanol  
 $C_6H_{11}ClN_4O$  110883-46-0 *antineoplastic*




ibutilidum  
ibutilide

( $\pm$ )-4'-[4-(ethylheptylamino)-1-hydroxybutyl]methanesulfonanilide  
 $C_{20}H_{36}N_2O_3S$  122647-31-8 *antidysrhythmic*




isalsteinium  
isalsteine

( $\pm$ )-*N*-[2-[(2-methyl-4-oxo-1,3-benzodioxan-2-yl)thio]propionyl]glycine  
 $C_{14}H_{15}NO_6S$  116818-99-6 *mucolytic*




ledazerolum  
ledazerol

2-hydroxy-3-(imidazol-4-yl)methylbenzyl alcohol  
 $C_{11}H_{12}N_2O_2$  116795-97-2 *antianginal*



levosulpiridum  
levosulpiride

(-)-*N*[[[*S*]-1-ethyl-2-pyrrolidinyl]methyl]-5-sulfamoyl- $\alpha$ -anisamide  
 $C_{15}H_{23}N_3O_4S$  23672-07-3 *antiemetic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


lisadimatum  
lisadimate

(±)-glycerol 1-(*p*-aminobenzoate)  
C<sub>10</sub>H<sub>13</sub>NO<sub>4</sub> 136-44-7 *sunscreen*




lometrexolum  
lometrexol

*N*-[*p*-[2-[(*R*)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-*d*]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid  
C<sub>21</sub>H<sub>25</sub>N<sub>5</sub>O<sub>6</sub> 106400-81-1 *antineoplastic*




masoprocolum  
masoprocol

*meso*-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol  
C<sub>18</sub>H<sub>22</sub>O<sub>4</sub> 27686-84-6 *antineoplastic*




midesteinum  
cysteine

2-thiophenecarbothioic acid, *S*-ester with (±)-2-mercapto-*N*-(tetrahydro-2-oxo-3-thienyl)propionamide  
C<sub>12</sub>H<sub>13</sub>NO<sub>3</sub>S<sub>2</sub> 94149-41-4 *mutolytic*



miripiriii chloridum  
miripirium chloride

1-tetradecyl-4-picolinium chloride  
C<sub>20</sub>H<sub>34</sub>ClN 2748-88-1 *disinfectant*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use

mivazerolum  
mivazerol


$\alpha$ -imidazol-4-yl-2,3-cresotamide  
C<sub>11</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub> 125472-02-8

antianginal




modecainidum  
modecainide

(±)-2'-[2-(1-methyl-2-piperidyl)ethyl]vanillinide  
C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> 81329-71-7 antidyshhythmic




naroparcilum  
naroparol

*p*-[*p*-[(5-thio- $\beta$ -D-xylopyranosyl)thio]benzoyl]benzonitrile  
C<sub>18</sub>H<sub>17</sub>NO<sub>4</sub>S<sub>2</sub> 120819-70-7 antithrombotic




nemazolium  
nemazoline

2-(4-amino-3,5-dichlorobenzyl)-2-imidazoline  
C<sub>10</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>3</sub> nasal vasoconstrictor



neticonazolum  
neticonazole

(*E*)-1-[2-(methylthio)-1-[ $\alpha$ -(pentyloxy)phenyl]vinyl]imidazole  
C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>OS 11178-99-9 antifungal




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


nicoracetamum  
nicoracetam

1-(6-methoxynicotinoyl)-2-pyrrolidinone  
 $C_{11}H_{12}N_2O_3$  128326-80-7 *nootropic agent*




ormaplatinum  
ormaplatin

(±)-*trans*-tetrachloro(1,2-cyclohexanediamine)platinum  
 $C_6H_{14}Cl_4N_2Pt$  62816-98-2 *antineoplastic*



otenzepadum  
otenzepad

(±)-11-[[2-[(diethylamino)methyl]piperidino]acetyl]-5,11-dihydro-6*H*-pyrido[2,3-*b*][1,4]benzodiazepin-6-one  
 $C_{24}H_{31}N_5O_2$  100158-38-1 *antibradycardic agent*




pegademasum  
pegademase

adenosine deaminase, reaction product with succinic anhydride, esters with polyethylene glycol monomethyl ether  
The source of the product should be indicated  
*enzyme*


pidotimodum  
pidotimod

(*R*)-3-[(*S*)-5-oxopropyl]-4-thiazolidinecarboxylic acid  
 $C_9H_{12}N_2O_4S$  121808-62-6 *immunomodulator*



pirodavirum  
pirodavir

ethyl *p*-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidyl]ethoxy]benzoate  
 $C_{21}H_{27}N_3O_3$  124436-59-5 *antiviral*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


prisotinolum  
prisotinol

(±)-6-[2-(isopropylamino)propyl]-3-pyridinol  
 $C_{11}H_{14}N_2O$  78997-40-7 *nootropic agent*




propagermanium  
propagermanium

polymer obtained from 3-(trihydroxygermyl)propionic acid  
( $C_3H_5GeO_{3.5}$ )<sub>n</sub> *immunomodulator*





remacemidum  
remacemide

(±)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide  
 $C_{17}H_{20}N_2O$  128298-28-2 *antiepileptic*




repagermanium  
repagermanium

poly-*trans*-[(2-carboxyethyl)germasquioxane]  
( $C_{18}H_{30}Ge_4O_{21}$ )<sub>n</sub> *immunomodulator*



rispenzepinum  
rispenzepine

(±)-6,11-dihydro-11-(1-methylpiperidoyl)-5*H*-pyrido[2,3-*b*][1,5]benzo-  
diazepin-5-one  
 $C_{19}H_{20}N_4O_2$  96449-05-7 *antispasmodic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


roxadimatum  
roxadimate

ethyl (±)-*p*-[bis(2-hydroxypropyl)amino]benzoate  
C<sub>15</sub>H<sub>23</sub>NO<sub>4</sub> 58882-17-0 *sunscreen*




sarpogrelatum  
sarpogrelate

(±)-2-(dimethylamino)-1-[[*o*-(*m*-methoxyphenethyl)phenoxy]methyl]ethyl  
hydrogen succinate  
C<sub>24</sub>H<sub>31</sub>NO<sub>6</sub> 125926-17-2 *platelet aggregation inhibitor*




serazapinum  
serazapine

methyl (±)-1,3,4,16b-tetrahydro-2-methyl-2*H*,10*H*-indolo[2,1-*c*]pyrazino-  
[1,2-*a*][1,4]benzodiazepine-16-carboxylate  
C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub> 115313-22-9 *anxiolytic*



siltenzepinum  
siltenzepine

5-[*N,N*-bis(2-hydroxyethyl)glycyl]-8-chloro-5,10-dihydro-11*H*-  
dibenzo[*b,e*][1,4]diazepin-11-one  
C<sub>18</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>4</sub> 98374-54-0 *antulcer*



somagrebiovum  
somagrebove

1-[*N*<sup>2</sup>-(*N*-L-methionyl-L-*α*-aspartyl)-L-glutamine]growth hormone (ox reduced)  
C<sub>987</sub>H<sub>1554</sub>N<sub>268</sub>O<sub>281</sub>S<sub>8</sub> 96353-48-9 *growth hormone*

*Proposed International  
Nonproprietary Name (Latin, English)*


*Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use*

somavubovum  
somavubove

127-L-leucinegrowth hormone (ox)  
 $C_{976}H_{1533}N_{263}O_{288}S_4$  126752-39-4 *growth hormone (vet.)*


sparfloxacinum  
sparfloxacin

5-amino-1-cyclopropyl-7-(*cis*-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid  
 $C_{19}H_{22}F_2N_4O_3$  110871-86-8 *antibacterial*




spiriprostilum  
spiriprostil

(±)-(5*R*\*,6*S*\*,7*R*\*)-7-hexyl-2,4-dioxo-1,3-diazaspiro[4,4]nonane-6-heptanoic acid  
 $C_{20}H_{34}N_2O_4$  122946-42-3 *antiulcer*




sucrosofatum  
sucrosofate

sucrose octakis(hydrogen sulfate)  
 $C_{12}H_{22}O_{35}S_8$  57680-56-5 *antiulcer*



sulazurilum  
sulazuril

2-[3,5-dichloro-4-[*p*-(methylsulfonyl)phenoxy]phenyl]dihydro-1-methyl-*as*-triazine-3,5-(2*H*,4*H*)-dione  
 $C_{17}H_{15}Cl_2N_3O_5S$  108258-89-5 *coccidiostatic*



suleparoidum natrium  
suleparoid sodium


heparitin sulfate, sodium salt  
 $(C_{14}H_{16}NO_{17}S_2Na_3)_n$  57459-72-0 *fibrinolytic*

Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


sulofenurum  
sulofenur

1-(*p*-chlorophenyl)-3-(5-indanylsulfonyl)urea  
C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>3</sub>S 110311-27-8 *antineoplastic*




sulukastum  
sulukast

3-[[[(1*R*,2*E*,4*Z*)-1-[(*aS*)-*a*-hydroxy-*m*-1*H*-tetrazol-5-ylbenzyl]-2,4-tetradecadienyl]thio]propionic acid  
C<sub>25</sub>H<sub>36</sub>N<sub>4</sub>O<sub>3</sub>S 98116-53-1 *antiasthmatic*




taurosteinum  
taurosteine

*N*-2-thenoyltaurine  
C<sub>7</sub>H<sub>9</sub>NO<sub>4</sub>S<sub>2</sub> 124066-33-7 *muco lytic*




tebufelonum  
tebufelone

3',5'-di-*tert*-butyl-4'-hydroxy-5-hexynophenone  
C<sub>20</sub>H<sub>28</sub>O<sub>2</sub> 112018-00-5 *nonsteroidal anti-inflammatory*



technetium(<sup>99m</sup>Tc) siboroximum  
technetium(<sup>99m</sup>Tc) siboroxime

[bis{[(2,3-butanedione dioximato)(1-)-*O*][(2,3-butanedione dioximato)(2-)-*O*]isobutylborato(2-)-*N,N', N'', N''', N''''*,  
*N''''''*]chloro[<sup>99m</sup>Tc]technetium(III)  
C<sub>16</sub>H<sub>29</sub>BClN<sub>6</sub>O<sub>6</sub><sup>99m</sup>Tc 106417-28-1 *diagnostic agent*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


telmesteinum  
telmesteine

(-)-3-ethyl hydrogen (R)-3,4-thiazolidinedicarboxylate  
C<sub>7</sub>H<sub>11</sub>NO<sub>4</sub>S 122946-43-4 *mucoytic*




tenosajum  
tenosal

2-thiophenecarboxylic acid, ester with salicylic acid  
C<sub>12</sub>H<sub>8</sub>O<sub>4</sub>S 95232-68-1 *nonsteroidal anti-inflammatory, analgesic*




tenosiprolum  
tenosiprol

(R)-4-hydroxy-L-proline 2-thiophenecarboxylate (ester)  
C<sub>10</sub>H<sub>11</sub>NO<sub>4</sub>S *nonsteroidal anti-inflammatory*




terbequiniolum  
terbequinil

1,4-dihydro-1-(methoxymethyl)-4-oxo-N-propyl-3-quinolinecarboxamide  
C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> 113079-82-6 *partial benzodiazepine receptor inverse agonist*



tiagabinum  
tiagabine

(-)-(*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]piperidine-2-carboxylic acid  
C<sub>20</sub>H<sub>25</sub>NO<sub>2</sub>S<sub>2</sub> 115103-54-3 *antiepileptic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


tirilazadum  
tirilazad

21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16 $\alpha$ -methylpregna-  
1,4,9(11)-triene-3,20-dione  
 $C_{38}H_{52}N_6O_2$  110101-66-1 *lipid peroxidation inhibitor*




utibaprilum  
utibapril

(*S*)-2-*tert*-butyl-4-[(*S*)-*N*[(*S*)-1-carboxy-3-phenylpropyl]alanyl]-4<sup>k</sup>-1,3,4-  
thiadiazoline-5-carboxylic acid, 4-ethyl ester  
 $C_{22}H_{31}N_3O_5S$  109683-61-6 *angiotensin converting enzyme inhibitor*




vanoxerinum  
vanoxerine

1-[2-[bis(*p*-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine  
 $C_{28}H_{32}F_2N_2O$  67469-69-6 *antidepressant, antiparkinsonian*



zeniplatinum  
zeniplatin

*cis*-[2,2-bis(aminomethyl)-1,3-propanediol](1,1-cyclobutane-  
dicarboxylato)platinum  
 $C_{11}H_{20}N_2O_8Pt$  111490-36-9 *antineoplastic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


zilascorbum (2H)  
zilascorb (2H)

5,6-O-[(*RS*)-benzylidene- $\alpha$ -L]-L-ascorbic acid  
C<sub>13</sub>H<sub>11</sub>DO<sub>6</sub> 122431-96-3 *antineoplastic*




zileutonum  
zileuton

( $\pm$ )-1-(1-benzo[*b*]thien-2-ylethyl)-1-hydroxyurea  
C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S 111406-87-2 *leukotriene synthesis inhibitor*



zofenoprilatum  
zofenoprilat

(4*S*)-1-[(*S*)-3-mercapto-2-methylpropionyl]-4-(phenylthio)-L-proline  
C<sub>15</sub>H<sub>19</sub>NO<sub>3</sub>S<sub>2</sub> 75176-37-3 *angiotensin-converting enzyme inhibitor*



## Names for Radicals and Groups


Some substances for which a proposed international non-proprietary name has been established may be used in the form of salts or esters. The radicals or groups involved

may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals

and groups have been devised or selected, and they are suggested for use with the proposed international non-proprietary names.


docosilum  
docosil

docosyl  
 $C_{22}H_{45}$



xinafoas  
xinafoate

1-hydroxy-2-naphthoate  
 $C_{11}H_7O_3$



# AMENDMENTS TO PREVIOUS LISTS

## WHO Drug Information Vol. 1, No. 3, 1987

### Proposed International Nonproprietary Names (Prop. INN): List 58

p. 188 saruplasum  
saruplase

replace the definition and the molecular formula by the following:  
prourokinase (enzyme-activating) (human clone pUK4/pUK18)  
 $C_{2037}H_{3121}N_{585}O_{601}S_{37}$

## WHO Drug Information Vol. 2, No. 2, 1988

### Proposed International Nonproprietary Names (Prop. INN): List 59

p. 9 muroderminum  
murodermin

replace the molecular formula and the CAS registry number by the following:  
 $C_{257}H_{375}N_{73}O_{83}S_7$  54017-73-1

## WHO Drug Information Vol. 3, No. 2, 1989


### Proposed International Nonproprietary Names (Prop. INN): List 61

p. 9 delete  
  
emonapridum  
emonapride

insert  
  
nemonapridum  
nemonapride

p. 14 moxidectinum  
moxidectin


replace the graphic formula by the following:



p. 18 tenidapum  
tenidap


replace the chemical name, the CAS registry number and the graphic formula by the following:

(Z)-5-chloro-3-( $\alpha$ -hydroxy-2-thenylidene)-2-oxo-1-indolinecarboxamide  
120210-48-2



**Proposed International Nonproprietary Names (Prop. INN): List 62**

- |       |   |   |
|-------|---|---|
| p. 3  | brifentanilum<br>brifentanil                      | <i>replace the chemical name by the following:</i><br>$(\pm)$ - <i>cis-N</i> -[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide            |
| p. 4  | ciclesonidum<br>ciclesonide                       | <i>add the following CAS number.</i><br>126544-47-6   |
| p. 5  | <i>delete</i><br><br>dapropterinum<br>dapropterin | <i>insert</i><br><br>sapropterinum<br>sapropterin   |
| p. 18 | etomoxirum<br>etomoxir                            | <i>replace the chemical name, the CAS registry number and the graphic formula by the following:</i><br>ethyl (+)-( <i>R</i> )-2-[6-( <i>p</i> -chlorophenoxy)hexyl]glycidate<br>124083-20-1 |



## Annex 1 PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES\*

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA3.11<sup>1</sup>.

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*<sup>2</sup> and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

- (i) set forth the name under consideration;
- (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;
- (iii) identify the substance for which a name is being considered;
- (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;
- (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>3</sup>

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>3</sup>

A. Such objection shall:

- (i) identify the person objecting;
- (ii) state his interest in the name;
- (iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name.

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the nonproprietary name for the substance, and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

\* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 50, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1959, 10).

<sup>1</sup> The title of this publication was changed in the *WHO Chronicle* in January 1959. From 1957 onwards lists of INNs are published in *WHO Drug Information*.

## GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological,

pathological or therapeutic suggestion should be avoided.

*These primary principles are to be implemented by using the following secondary principles*

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. "oxacillin" and "oxacillin sodium", "ibufenac" and "ibufenac sodium".

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ

only in respect of the name of the inactive acid or the inactive base.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6 The use of an isolated letter or number should be avoided, hyphenated construction is also undesirable

7. To facilitate the translation and pronunciation of INN, "f" should be

used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y", the use of the letters "h" and "k" should be avoided.

8 Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration

9 Group relationship in INN (see Guiding Principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use<sup>1</sup> Where a stem is shown without any hyphens it may be used anywhere in the name.

<i>Latin</i>	<i>English</i>	
-acum	-ac	anti-inflammatory agents of the ibufenac group
-actidum	-actide	synthetic polypeptides with a corticotrophin-like action
-adolum	-adol	} analgesics
-adol-	-adol-	
-astum	-ast	anti-asthmatic, anti-allergic substances not acting primarily as antihistaminics
-astinum	-astine	antihistaminics
-azepamum	-azepam	substances of the diazepam group
-bactamum	-bactam	$\beta$ -lactamase inhibitors
bol	bol	steroids, anabolic
-buzonium	-buzone	anti-inflammatory analgesics of the phenylbutazone group
-cain-	-cain-	antifibrillant substances with local anaesthetic activity
-cainum	-caine	local anaesthetics
cef-	cef-	antibiotics, derivatives of cefalosporanic acid
-cillinum	-cillin	antibiotics, derivatives of 6-aminopenicillanic acid
-conazolum	-conazole	systematic antifungal agents of the miconazole group
cort	cort	corticosteroids, except those of the prednisolone group
-dipinum	-dipine	calcium antagonists of the nifedipine group
-fibratum	-fibrate	substances of the clofibrate group
gest	gest	steroids, progestogens
gli-	gli-	sulfonamide hypoglycemics
io-	io-	iodine-containing contrast media
-ium	-ium	quaternary ammonium compounds
-metacinum	-metacin	anti-inflammatory substances of the indometacin group
-mycinum	-mycin	antibiotics, produced by <i>Streptomyces</i> strains
-nidazolum	-nidazole	antiprotozoal substances of the metronidazole group
-ololum	-olol	$\beta$ -adrenergic blocking agents
-oxacinum	-oxacin	antibacterial agents of the nalidix acid group
-pridum	-pride	sulpiride derivatives
-pril(at)um	pril(at)	angiotensin-converting enzyme inhibitors
-profenum	-profen	anti-inflammatory substances of the ibuprofen group
p	prost	prostaglandins
-retinum	-relin	hypophyseal hormone release-stimulating peptides
-terolum	-terol	bronchodilators, phenethylamine derivatives
-tidinum	-tidine	H <sub>2</sub> -receptor antagonists
-trexatum	-trexate	folic acid antagonists
-verinum	-verine	spasmolytics with a papaverine-like action
vin-	vin-	} vinca type alkaloids
-vin-	-vin-	

<sup>1</sup> A more extensive listing of stems is contained in the working document Pharm S/Nom 15 which is regularly updated and can be requested from Pharmaceuticals, WHO, Geneva

**Annex 2**  
**NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES:**  
**TWENTIETH REPORT OF THE WHO EXPERT COMMITTEE**

In its twentieth report<sup>1</sup> the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, international nonproprietary names (INN) in the light of developments in pharmaceutical compounds in recent years. The most significant recent change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves employing a characteristic "stem" indicative of a common property of the members of a group. The reasons for, and the implications of, the change are fully discussed. Also

reported is the intention to change the practice with regard to the nomenclature of individual members of polymeric series.

Other sections of the report concern instructions to be followed by bodies making application for international nonproprietary names, the availability of computer-printed cumulative lists of international nonproprietary names, information supplied by WHO Member States concerning their official use of national or international names for pharmaceutical products, and proposals relative to the withdrawal of international nonproprietary names allocated to substances that are no longer in use.

The official texts relating to the procedures for selecting, and general

guidance for devising, international nonproprietary names are reproduced in two annexes to the report. Other annexes give examples of international nonproprietary names that incorporate selected stems, the most frequently used initial groups of letters in international nonproprietary names, a historical review of the programme of selecting international nonproprietary names, some useful literature references, and a model of the form to be used in all applications for international nonproprietary names.

<sup>1</sup> WHO Technical Report Series, No. 581, 1975.  
(Nonproprietary Names for Pharmaceutical Substances Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 Price Sw fr. 6.-